Tuberculin skin testing in patients with HIV infection: Limited benefit of reduced cutoff values

Clinical Infectious Diseases

Volumn 43, Issue 5, 2006, Pages 634-639

  Cobelens, Frank G ^a,b   Egwaga, Saidi M ^c   Van Ginkel, Tessa ^b   Muwinge, Hemed ^c   Matee, Mecky I ^c   Borgdorff, Martien W ^a,b  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SKIN TEST; SPUTUM EXAMINATION; TUBERCULIN TEST;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TANZANIA; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33747612657     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506432     Document Type: Article

References (38)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
2. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Article no.: CD000171. Digital object identifier: 10.1002/14651858.CD000171.pub2. Oxford, United Kingdom: Cochrane database of systematic reviews, 2004.
3. Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 1999; 13:1549-56.
4. World Health Organziation. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2004.
5. Menzies R. Tuberculin skin testing. In: Reichman LB, Hershfield ES, eds. Tuberculosis: a comprehensive international approach. 2nd ed. New York: Marcel Dekker, 2000:279-302.
6. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
7. Long R, Houston S, Hershfield E. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. CMAJ 2003; 169:789-91.
8. Huebner RE, Villarino ME, Snider DE Jr. Tuberculin skin testing and the HIV epidemic. JAMA 1992; 267:409-10.
9. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268:504-9.
10. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993; 119:177-84.
11. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000; 283:2003-7.
12. Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267:369-73.
13. Johnson MP, Coberly JS, Clermont HC, et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166:194-8.
14. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194-8.
15. Gourevitch MN, Hartel D, Schoenbaum EE Klein RS. Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med 1996; 154:1029-33.
16. Garcia-Garcia ML, Valdespino-Gomez JL, Garcia-Sancho C, et al. Underestimation of Mycobacterium tuberculosis infection in HIV-infected subjects using reactivity to tuberculin and anergy panel. Int J Epidemiol 2000; 29:369-75.
17. Klein RS, Gourevitch MN, Teeter R, Schoenbaum EE. The incidence of tuberculosis in drug users with small tuberculin reaction sizes. Int J Tuberc Lung Dis 2001; 5:707-11.
18. Egwaga SM, Cobelens FG, Muwinge H, Verhage C, Kalisvaart N, Borgdorff MW. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 2006; 20:915-21.
19. Arnadottir T, Rieder HL, Trebucq A, Waaler HT. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tuber Lung Dis 1996; 77(Suppl 1):1-19.
20. Comstock G, Edwards L, Philip R, Winn W. A comparison in the United States of America of two tuberculins, PPD-S and RT23. Bull World Health Organ 1964; 31:161-70.
21. Delgado JC, Tsai EY, Thim S, et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci U S A 2002; 99:7576-81.
22. Rooney JJ Jr., Crocco JA, Kramer S, Lyons HA. Further observations on tuberculin reactions in active tuberculosis. Am J Med 1976; 60:517-22.
23. Khan MA, Kovnat DM, Bachus B, Whitcomb ME, Brody JS, Snider GL. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977; 62:31-8.
24. McMurray DN, Echeverri A. Cell-mediated immunity in anergic patients with pulmonary tuberculosis. Am Rev Respir Dis 1978; 118:827-34.
25. Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis: a comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest 1980; 77:32-7.
26. Corbett EL, Churchyard GJ, Clayton T, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners: a case-control study. Am J Respir Crit Care Med 1999; 159:94-9.
27. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:Suppl:1-132.
28. Eilers PH, Borgdorff MW. Modeling and correction of digit preference in tuberculin surveys. Int J Tuberc Lung Dis 2004; 8:232-9.
29. Mukadi Y, Perriens JH, St Louis ME, et al. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993; 342:143-6.
30. Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van de Perre P. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992; 146:53-6.
31. Schwander SK, Dietrich M, Mugyenyi P, et al. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. East Afr Med J 1997; 74:543-8.
32. Richter C, Perenboom R, Swai AB, et al. Diagnosis of tuberculosis in patients with pleural effusion in an area of HIV infection and limited diagnostic facilities. Trop Geogr Med 1994; 46:293-7.
33. Caiaffa WT, Graham NM, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111-7.
34. Anastos K, Kalish LA, Palacio H, et al. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 1999; 21:141-7.
35. Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, Borgdorff MW. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis 2005; 9:310-6.
36. Fine PE, Floyd S, Stanford JL, et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 2001; 126:379-87.
37. Rieder HL. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis 1995; 76:114-21.
38. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998. Int J Tuberc Lung Dis 2001; 5:103-12.